Brainstorm Cell Therapeutics Q2 2024 Earnings Report $1.23 +0.02 (+1.65%) As of 04/3/2025 04:00 PM Eastern Earnings HistoryForecast Brainstorm Cell Therapeutics EPS ResultsActual EPS-$0.60Consensus EPS -$0.60Beat/MissMet ExpectationsOne Year Ago EPS-$4.05Brainstorm Cell Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABrainstorm Cell Therapeutics Announcement DetailsQuarterQ2 2024Date8/14/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptBCLI Earnings History Remove Ads Brainstorm Cell Therapeutics Earnings HeadlinesEarnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cuttingApril 2 at 11:17 AM | uk.investing.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call TranscriptApril 1 at 9:39 AM | msn.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 4, 2025 | Porter & Company (Ad)BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateApril 1 at 1:29 AM | finanznachrichten.deQ4 2024 Brainstorm Cell Therapeutics Inc Earnings CallApril 1 at 1:29 AM | finance.yahoo.comBrainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comSee More Brainstorm Cell Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Brainstorm Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your email. Email Address About Brainstorm Cell TherapeuticsBrainstorm Cell Therapeutics (NASDAQ:BCLI), a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.View Brainstorm Cell Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
